Target Drug Market
UroPharma is uniquely positioned to bring a number of direct to bladder treatments to people with bladder diseases and disorders, notably people with neurological conditions, e.g. multiple sclerosis (MS) and spinal cord injuries (SCI), overactive bladder (OAB), bladder cancer, pain & inflammation and urinary tract infections (UTI). Research by a number of institutes, including the Centers for Disease Control and Prevention (CDC) and PR Newswire, has demonstrated that each of these 5 markets is growing year on year. UroPharma’s target markets can be further divided into two key sub-groups namely individuals who suffer from the ailments identified in the graphic above and the medical facilities that treat those individuals.
The bladder diseases and disorders markets are estimated to be worth over $19 billion. UroPharma can roll out drug-delivery combinations into each of the 5 target markets shown in the above graphic. The individual size and value of each of these markets justifies this business in their own right. In particular, due to the ongoing need for bladder management of people with multiple sclerosis and spinal cord injuries they may end up using UroPharma’s products everyday over their entire lifetimes.
Target Drug Market Opportunities
Due to the aging of populations, these $19 billion target markets are expected to increase.
UroPharma will initially enter the market with the dtb-instilla device combined with Atropine, a generic drug that has been shown to be effective for bladder overactivity in MS and SCI.
Feedback from research participants in MS trials carried out by Inventya Ltd (an independent market research organization) has shown a clear preference by patients and urologists for this form of therapy compared with conventional oral therapy. This has been further validated through independent market research carried out by Inventya Ltd in 2015 and supports UroPharma’s strategic priority. In particular, according to research carried out in 2018 by Cleveland Clinic (a reputable non-profit academic medical center), there is an estimated 2.5 million people with MS worldwide and 1 million in the US alone; although this US estimate is substantially higher than others. We have based our market projections on an estimated of 400,000 people with MS in North America. Additionally, the Multiple Sclerosis International Federation (MSIF) estimates that 10,000 new cases are diagnosed every year in the US (that’s 200 new cases per week). Of all those people, it is anticipated that up to 90% will experience bladder problems.
UroPharma’s initial strategy is to bring dtb therapeutics to people with MS in the US, UK and Europe. UroPharma’s own market research indicates that many people with MS (who are already self-catheterizing) will choose dtb therapy throughout their lives because of its effectiveness and minimal side effect profile, which translates to a potential recurring revenue stream for UroPharma of up to $12,000 annually per user (based on 2 doses a day with a cost of $15.50 per dose).